Generex Biotechnology Corp. is an integrated healthcare holding company with end-to-end solutions for patient centric care from rapid diagnosis through delivery of personalized therapies. The company is headquartered in Miramar, Florida. The firm is engaged in pharmaceutical and biotechnological research and development and other activities. Its subsidiary, NuGenerex Immuno-Oncology, Inc., is focused on the modulation of the immune system and activation of T cells to treat cancer. Its lead cancer immunotherapy product candidate is AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer, which links its li-Key to a designated tumor antigen like HER-2 to activates the immune system to target specific cancer cells. NuGenerex Health LLC provides ancillary health services in the areas of eyecare, podiatry and chronic care management. NuGenerex Regenerative Medicine is focused on developing drugs, medical devices and therapeutics to improve treatment outcomes. Nugenerex Diagnostics, Inc. manufactures in-vitro medical diagnostic devices for both point of care and laboratory-based tests, primarily for infectious diseases.